Skip Ribbon Commands
Skip to main content
Navigate Up
EnglishFrancais
Current Year Centre for Addiction
and Mental Health

CAMH welcomes announcement that Health Canada will allow access to naloxone nasal spray

​TORONTO, July 7, 2016 - CAMH welcomes the federal government’s announcement that Health Canada will allow immediate access to naloxone nasal spray.

Naloxone has been used as an antidote for opioid overdose in hospital and paramedic settings for decades. It is known to be safe, and in places where it has been widely distributed, naloxone has helped stem fatal overdoses. Beyond that, naloxone can decrease survivors’ later frequency of injection and increase the likelihood that they will enter treatment.

Until now, naloxone has only been available in Canada as an intra-muscular injection, and until recently, multiple regulatory barriers prevented broad distribution of naloxone to users as well as to their family and friends – who are the ones most likely to be nearby and in a position to help in case of an overdose. Recent moves by federal and provincial governments to make naloxone available without a prescription and to provide it to correctional facilities and staff were important steps that will facilitate access. Now, the introduction of naloxone in its nasal spray formulation, which is easier to distribute and deliver, will allow first responders as well as friends and family to more easily administer naloxone.

Solving the opioid crisis will require sustained action on multiple fronts. In the meantime we can – and must – do more to prevent overdose deaths. The recently announced measures, including allowing access to naloxone nasal spray, will help achieve that.

CAMH Switchboard 416-535-8501
CAMH General Information Toronto: 416-595-6111 Toll Free: 1-800-463-6273
Connex Ontario Help Lines
Queen St.
1001 Queen St. W
Toronto, ON
M6J 1H4
Russell St.
33 Russell St.
Toronto, ON
M5S 2S1
College St.
250 College St.
Toronto, ON
M5T 1R8
Ten offices across Ontario